I-Tech AB (ITECH.ST)
SEK 83.0
(7.79%)
SEK 83.0
(7.79%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 20.2 Million SEK | 90.29% |
| 2022 | 10.61 Million SEK | 500.94% |
| 2021 | -2.64 Million SEK | 44.9% |
| 2020 | -4.8 Million SEK | -157.03% |
| 2019 | 8.42 Million SEK | 161.35% |
| 2018 | -13.73 Million SEK | -63.19% |
| 2017 | -8.41 Million SEK | -17.82% |
| 2016 | -7.14 Million SEK | 16.9% |
| 2015 | -8.59 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 8.73 Million SEK | 6.74% |
| 2024 Q3 | 7.79 Million SEK | -10.85% |
| 2024 Q1 | 8.18 Million SEK | 2294.64% |
| 2023 Q1 | 6.66 Million SEK | 52.89% |
| 2023 FY | 20.2 Million SEK | 90.29% |
| 2023 Q4 | -373 Thousand SEK | -105.5% |
| 2023 Q3 | 6.78 Million SEK | -3.02% |
| 2023 Q2 | 6.99 Million SEK | 5.0% |
| 2022 Q1 | 511 Thousand SEK | 131.8% |
| 2022 FY | 10.61 Million SEK | 500.94% |
| 2022 Q4 | 4.35 Million SEK | 3.25% |
| 2022 Q3 | 4.21 Million SEK | 175.57% |
| 2022 Q2 | 1.53 Million SEK | 199.61% |
| 2021 Q1 | 415 Thousand SEK | 113.31% |
| 2021 Q3 | 925 Thousand SEK | 138.85% |
| 2021 Q4 | -1.6 Million SEK | -273.73% |
| 2021 FY | -2.64 Million SEK | 44.9% |
| 2021 Q2 | -2.38 Million SEK | -673.73% |
| 2020 Q4 | -3.11 Million SEK | -294.31% |
| 2020 Q3 | -791 Thousand SEK | -117.31% |
| 2020 Q1 | -532 Thousand SEK | -103.71% |
| 2020 FY | -4.8 Million SEK | -157.03% |
| 2020 Q2 | -364 Thousand SEK | 31.58% |
| 2019 Q2 | -1.04 Million SEK | 76.59% |
| 2019 FY | 8.42 Million SEK | 161.35% |
| 2019 Q4 | 14.35 Million SEK | 3592.21% |
| 2019 Q3 | -411 Thousand SEK | 60.71% |
| 2019 Q1 | -4.46 Million SEK | -49.27% |
| 2018 Q2 | -2.27 Million SEK | 32.29% |
| 2018 FY | -13.73 Million SEK | -63.19% |
| 2018 Q3 | -5.1 Million SEK | -124.73% |
| 2018 Q1 | -3.35 Million SEK | -54.84% |
| 2018 Q4 | -2.99 Million SEK | 41.39% |
| 2017 Q3 | -1.98 Million SEK | -27.4% |
| 2017 Q1 | -2.71 Million SEK | 0.0% |
| 2017 Q2 | -1.55 Million SEK | 42.68% |
| 2017 Q4 | -2.16 Million SEK | -9.44% |
| 2017 FY | -8.41 Million SEK | -17.82% |
| 2016 FY | -7.14 Million SEK | 16.9% |
| 2015 FY | -8.59 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| 2cureX AB (publ) | -32.51 Million SEK | 162.129% |
| Abliva AB (publ) | -95.5 Million SEK | 121.153% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 118.486% |
| AcouSort AB (publ) | -17.08 Million SEK | 218.222% |
| Active Biotech AB (publ) | -45.8 Million SEK | 144.111% |
| Alzinova AB (publ) | -16.48 Million SEK | 222.591% |
| Amniotics AB (publ) | -30.87 Million SEK | 165.445% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 145.86% |
| Aptahem AB (publ) | -11.11 Million SEK | 281.798% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | 257.491% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 108.127% |
| BioInvent International AB (publ) | -330.3 Million SEK | 106.116% |
| BioArctic AB (publ) | 229.24 Million SEK | 91.187% |
| Biosergen AB | -27.03 Million SEK | 174.724% |
| Biovica International AB (publ) | -124.82 Million SEK | 116.185% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 135.556% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 104.334% |
| Camurus AB (publ) | 431.44 Million SEK | 95.317% |
| Cantargia AB (publ) | -280.02 Million SEK | 107.215% |
| Corline Biomedical AB | -1.8 Million SEK | 1216.805% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | 195.79% |
| CombiGene AB (publ) | -35.66 Million SEK | 156.646% |
| Cyxone AB (publ) | -22.98 Million SEK | 187.881% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | 273.001% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 113.305% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 106.18% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | 223.204% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 122.104% |
| Fluicell AB (publ) | -26.55 Million SEK | 176.083% |
| Genovis AB (publ.) | 61.5 Million SEK | 67.15% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 117.828% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 102.429% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 116.416% |
| Mendus AB (publ) | -101.61 Million SEK | 119.881% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 111.36% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 154.498% |
| Intervacc AB (publ) | -102.85 Million SEK | 119.643% |
| Kancera AB (publ) | -64.88 Million SEK | 131.135% |
| Karolinska Development AB (publ) | 5.38 Million SEK | -275.102% |
| LIDDS AB (publ) | -40.2 Million SEK | 150.249% |
| Lipum AB (publ) | -37.17 Million SEK | 154.341% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | 266.581% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | -66.02% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | 212.885% |
| Nanologica AB (publ) | -75.15 Million SEK | 126.881% |
| NextCell Pharma AB | -41.95 Million SEK | 148.148% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 108.11% |
| OncoZenge AB (publ) | -15.9 Million SEK | 227.047% |
| Pila Pharma AB (publ) | -9.93 Million SEK | 303.454% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | 222.272% |
| Saniona AB (publ) | -95.81 Million SEK | 121.087% |
| Simris Alg AB (publ) | -37.3 Million SEK | 154.156% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 147.848% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | 4712.557% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 185.112% |
| SynAct Pharma AB | -215.81 Million SEK | 109.361% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 106.497% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 105.205% |
| Xintela AB (publ) | -54.08 Million SEK | 137.356% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 111.245% |
| Ziccum AB (publ) | -21.41 Million SEK | 194.354% |